Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCIMAGING.119.009709DOI Listing

Publication Analysis

Top Keywords

severe late-onset
4
late-onset fabry
4
fabry cardiomyopathy
4
cardiomyopathy unmasked
4
unmasked multimodality
4
multimodality imaging
4
imaging approach
4
severe
1
fabry
1
cardiomyopathy
1

Similar Publications

Conventionally, dose finding trials are based on dose-limiting toxicity (DLT) that only captures the most severe toxicities, e.g., treatment related grade 3 or higher toxicity according to the NCI Common Terminology Criteria for Adverse Events.

View Article and Find Full Text PDF

Background Diffuse idiopathic skeletal hyperostosis (DISH) is an age-related condition involving abnormal ossification of soft tissues, including ligaments and joint capsules. Patients with DISH have an increased risk of fractures, especially in ankylosed spines, which increases susceptibility to spinal cord injury. This study aimed to explore the risk factors for neurological symptoms in patients with DISH-related fractures.

View Article and Find Full Text PDF

Background: Developmental regression in children, in the absence of neurological damage or trauma, presents a significant diagnostic challenge. The complexity is further compounded when it is associated with psychotic symptoms.

Method: We discuss a case series of ten children aged 6-10 years, with neurotypical development, presenting with late-onset developmental regression (>6 years of age), their clinical course and outcome at 1 year.

View Article and Find Full Text PDF

Objectives: We aim to investigate cognitive phenotype distribution and MRI correlates across pediatric-, elderly-, and adult-onset MS patients as a function of disease duration.

Methods: In this cross-sectional study, we enrolled 1262 MS patients and 238 healthy controls, with neurological and cognitive assessments. A subset of 222 MS patients and 92 controls underwent 3T-MRI scan for brain atrophy and lesion analysis.

View Article and Find Full Text PDF

: Early-onset breast cancer (EOBC), particularly in patients under 40, presents with distinct biological characteristics and worse survival outcomes compared to late-onset cases. Despite intensive treatments, EOBC patients, especially those with hormone receptor-positive, HER2-negative (HR+/HER2-) subtypes, show poorer prognosis. CDK4/6 inhibitors, combined with endocrine therapy (ET) have become the standard for HR+/HER2- metastatic breast cancer, yet younger patients are underrepresented in clinical trials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!